What inbiose does

Inbiose is a Belgian B2B biotechnology company founded in 2013 as a Ghent University spin-off that develops and manufactures specialty carbohydrate ingredients—primarily Human Milk Oligosaccharides (HMOs)—using precision fermentation and synthetic biology. Operating from Zwijnaarde, Belgium with approximately 50 employees, the company serves four primary application segments: early life nutrition (infant formula and toddler products), dietary supplements and medical nutrition, functional food and beverages, and pet nutrition/animal feed. Its commercial portfolio comprises six individual HMO ingredients (GlycoActive™ 2'-FL, 3'-FL, 3'-SL, 6'-SL, LNT, LNnT) and three proprietary blends (3-HMO, 5-HMO, and 6-HMO) targeting gut, immune, metabolic, and cognitive health outcomes.

The company's core technology is the proprietary GlycoActives® platform, which combines a microbial strain library of 70,000+ strains, a 2,000+ enzyme library, capability to develop 30+ glycans, automated robotic high-throughput screening, and machine learning-driven strain optimization. This stack enables a documented 12-month molecule-to-pilot-scale cycle. Manufacturing is asset-light: in-house lab-scale fermentation for optimization is paired with external partners for scale-up to 66 metric tons. Multi-jurisdiction regulatory clearances—FDA GRAS for five HMOs, EFSA Novel Food approval, full Chinese approval for 2'-FL, and Canadian authorization for 2'-FL (May 2025)—form the regulatory backbone of the business.

Inbiose operates a sales-led go-to-market with direct enterprise engagement, inside sales for mid-market, and event-driven demand generation at industry conferences (ESPGHAN, Vitafoods Europe, Future Food Tech). Revenue is generated via quote-based, multi-year B2B ingredient supply contracts with flexible MOQs for both pilot and commercial-scale volumes; pricing is not publicly disclosed. The company has raised €15 million in non-dilutive debt financing from the European Investment Bank (2023), maintains a strategic relationship with Danone Ventures, and in April 2025 transitioned Dirk Abeel from CCO to CEO while co-founder Prof. Wim Soetaert moved to Executive Chairman, signaling a shift from R&D-led to commercial-scaling focus.

Name

inbiose

Legal name

Inbiose NV

Website

https://inbiose.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Inbiose is a Belgian B2B biotech company that produces nature-identical Human Milk Oligosaccharides via precision fermentation for B2B customers in infant nutrition, dietary supplements, functional food and beverage, and pet nutrition markets.

Ownership category

akta.pro rank

Product category

Specialty Biotechnology Ingredients (Human Milk Oligosaccharides)

NAICS

Food Manufacturing (311)

SIC

Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors) (EUAAAIAJ)

akta.pro secondary industries

Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI), Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Human milk oligosaccharides
• Precision fermentation ingredients
• Specialty carbohydrate manufacturing
• Synthetic biology platform
• HMO ingredient supplier

Headquarters

HQ city

Zwijnaarde

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. HMO Ingredient Sales: Sale of Human Milk Oligosaccharide ingredients (individual HMOs and proprietary blends) to manufacturers of infant nutrition, dietary supplements, functional foods, beverages, pet nutrition, and animal feed products.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Inbiose develops and manufactures nature-identical Human Milk Oligosaccharide (HMO) ingredients and proprietary multi-HMO blends using its proprietary GlycoActives® precision fermentation platform. The company sells six individual HMO ingredients (2'-FL, 3-FL, 3'-SL, 6'-SL, LNT, LNnT) and proprietary blends to B2B customers in infant nutrition, dietary supplements, functional food & beverage, medical nutrition, pet nutrition, and animal feed markets worldwide.

Product overview

Inbiose's product portfolio centers on its GlycoActives® technology platform, which enables precision fermentation production of human milk oligosaccharides (HMOs). The offering comprises six individual HMO ingredients (GlycoActive™ 2FL, 3SL, LNT, 3FL, 6SL, and LNnT) as single-pure ingredients for targeted formulations, alongside three proprietary GlycoActives™ Blends (3 HMO, 5 HMO, and 6 HMO blends) combining multiple glycans for synergistic gut, cognition, and immune health effects. All products are produced via sustainable precision fermentation, are GRAS/EFSA-approved, and target applications across early life nutrition, dietary supplements, functional foods and beverages, pet nutrition, and animal feed.

Differentiator

Problem solved

Functional benefit

Brands

• GlycoActives: Proprietary platform using synthetic biology and precision fermentation to deliver bioactive carbohydrates including HMOs for health ingredients.
• GlycoActive™ HMOs

Products and services

• GlycoActive™ 2FL (2'-Fucosyllactose) The most abundant HMO in human milk, used for immune, gut, and metabolic health support across infant nutrition, dietary supplements, and functional foods.
• GlycoActive™ 3SL (3'-Sialyllactose) Sialylated HMO with immune health relevance, supporting microbiome modulation and cognitive development.
• GlycoActive™ LNT (Lacto-N-tetraose) Core neutral HMO found in high concentration in breast milk, supporting gut barrier function and beneficial bacteria colonization.
• GlycoActive™ 3FL (3-Fucosyllactose) HMO that rises significantly during lactation, supporting gut health and immune function.
• GlycoActive™ 6SL (6'-Sialyllactose) Most abundant sialylated HMO in milk, supporting immune health and cognitive development.
• GlycoActive™ LNnT (Lacto-N-neotetraose) HMO with unique prebiotic profile, supporting gut microbiota balance and immune function.
• 3 HMO Blend (Gut & Immune Blend) Proprietary blend of 3 HMOs designed for gut and immune health applications, combining multiple glycans for synergistic effects.
• 5 HMO Blend (Gut, Cognition & Immune Blend) Proprietary blend of 5 HMOs targeting gut health, cognitive function, and immune support, designed for advanced formulation needs.
• 6 HMO Blend (Gut, Cognition & Immune Blend) Comprehensive proprietary blend of 6 HMOs for gut, cognition, and immune health, representing the most complete HMO formulation in the portfolio.

Quantifiable outcome

• Regulatory clearance in 4 major markets (US, EU, China, Canada)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core and minor.

• European Innovation Council (EIC)coreStrategic or Co-development Partner · 24 July 2025EIC co-organized the Start & Scale-up Event with Impact Circle (Tomorrowland) where Inbiose participated. EIC supports European innovation and scale-ups in biotech and sustainable food sectors.
• Impact Circle (Tomorrowland)coreStrategic or Co-development Partner · 24 July 2025Impact Circle, the sustainability initiative of Tomorrowland festival, co-organized a Start & Scale-up Event with EIC where Inbiose pitched and networked with major corporations. Engaged in discussions about co-creating environmental and societal impact through strategic partnerships.
• The Coca-Cola CompanyminorStrategic or Co-development Partner · 24 July 2025Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.
• AB InBevminorStrategic or Co-development Partner · 24 July 2025Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.
• Procter & GambleminorStrategic or Co-development Partner · 24 July 2025Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Corbion: Fermentation-based food ingredients company producing lactic acid, algae-based ingredients, and functional food components. Comparable as a precision-fermentation platform targeting food, nutrition, and health applications.
• dsm-firmenich: Global nutrition and ingredients giant that absorbed HMO pioneer Glycom in 2020. Competes with Inbiose across HMOs, infant nutrition ingredients, and precision-fermented bioactives, with materially greater scale and capital.
• Novonesis (formerly Novozymes + Chr. Hansen): Merged bioscience platform combining microbial fermentation leadership (Novozymes) with Chr. Hansen's HMO programs (including the former Jennewein acquisition). Directly comparable fermentation-driven ingredient production serving similar CPG and nutrition customers.
• BASF: Chemicals and nutrition major with HMO programs targeted at infant formula and dietary supplements. Operates at vastly larger scale with broader ingredient portfolios overlapping Inbiose's precision-fermentation offerings.

Emerging players

• Sensus (Royal Cosun): Producer of chicory-derived inulin and prebiotic fibers used in gut-health formulations. Comparable as a supplier of prebiotic and gut-health ingredients to supplement and food manufacturers.
• AB Biotics: Biotech developing probiotic and microbiome-targeted ingredients for dietary supplements and functional foods. Comparable in applying microbiome science to commercial ingredient offerings across overlapping customer segments.

Direct peers

• Glycom (now part of dsm-firmenich): Pioneering HMO producer acquired by DSM in 2020 for ~€765M. Closest historical direct comparable in scale of HMO business, regulatory breadth, and precision-fermentation technology at acquisition time.
• ZuChem: US-based specialty carbohydrate producer using fermentation and biocatalysis for rare sugars and HMOs. Most directly comparable in technology stack (fermentation-based specialty carbs) and target markets (food, supplement, infant nutrition).
• Jennewein Biotechnologie: Pioneer HMO specialist focused on precision-fermented human milk oligosaccharides for infant nutrition. Now part of Chr. Hansen / Novonesis but historically a direct comparable specialty HMO producer targeting the same customers as Inbiose.

Others

• Kyowa Hakko Bio: Fermentation-derived amino acids, nucleotides, and bioactive ingredients for nutrition and pharma. Comparable as a fermentation-based specialty ingredient manufacturer serving overlapping dietary supplement and food customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInbe.linkedin.com/company/inbiose-n-v

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about inbiose